Division of Pfizer Inc.
Latest From Shiley Inc.
Microvention Inc., a three-year-old start-up, is developing minimally invasive devices for treating cerebral vascular conditions. Its is first focusing on developing a better devices for treating aneurysms. It has a hybrid device, combining coils with a sponge-like hydrogel material that fills the aneurysm, cutting it off from the blood vessel. This allows the blood vessel to heal and recover its full strength. The product is in pre-clinical trials.
Unlike their logistics-driven counterparts in the US, European hospital supply distributors have stressed their role as exclusive sales agents for selected manufacturers. But in Germany, cost pressures are forcing hospitals to look at process as much as product, leading suppliers like Krauth into an array of service-oriented, asset management-based businesses.
Six months after a significant management change, Zimmer officials claim the orthopedics leader is back on track. But in today's environment, can even a successful orthopedics company please its drug-company parent?
Pfizer's economic figuring goes something like this: an internally discovered drug, or one licensed for relatively little money at an early stage of development, can nonetheless be considerably less profitable than one in-licensed when it is nearly ready for NDA filing, even if the drug costs a small fortune in cash and quids.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.